- Conditions
- Myeloma, Plasma-Cell, Myeloma-Multiple, Myelomatosis
- Interventions
- Adoptive Immunotherapy, Rapamycin-Generated Autologous Th1/Tc1 Cells (modified primary human T cells), Th1/Tc1 Rapa Cell Therapy
- Procedure · Biological
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2017
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Hackensack, New Jersey
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Chronic Illness
- Interventions
- Virtual Acceptance Commitment Therapy
- Behavioral
- Lead sponsor
- Children's Hospital Los Angeles
- Other
- Eligibility
- 14 Years to 21 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Metastatic Breast Cancer
- Interventions
- huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells, huMNC2-CAR44 CAR T cells or huMNC2-CAR22 CAR T cells @ RP2D
- Biological
- Lead sponsor
- Minerva Biotechnologies Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2035
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Glioblastoma, Glioblastoma Multiforme
- Interventions
- EGFR BATs with TMZ following SOC RT/TMZ, Weekly EGFR BATs following SOC RT/TMZ
- Drug
- Lead sponsor
- University of Virginia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Charlottesville, Virginia
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia, in Relapse
- Interventions
- DC/AML Fusion Vaccine, T-Cell Therapy, Decitabine, Venetoclax, GM-CSF
- Biological · Drug
- Lead sponsor
- David Avigan
- Other
- Eligibility
- Not listed
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Acute Myeloid Leukemia
- Interventions
- G-CSF, Cytarabine, Fludarabine, Donor Natural Killer (NK) cells, ALT-801
- Drug · Biological
- Lead sponsor
- Altor BioScience
- Industry
- Eligibility
- 2 Years to 59 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Relapsed/Refractory Aggressive B-Cell Malignancies
- Interventions
- ONCT-808, Bridging Therapy
- Biological · Drug
- Lead sponsor
- Oncternal Therapeutics, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 4
- States / cities
- Duarte, California • Boston, Massachusetts • Houston, Texas
- Conditions
- Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
- Interventions
- Aldesleukin, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, NGFR-transduced Autologous T Lymphocytes, TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes
- Biological · Drug · Other
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 12 Years to 70 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2027
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Infection, Precancerous/Nonmalignant Condition
- Interventions
- therapeutic allogeneic lymphocytes, allogeneic bone marrow transplantation, total-body irradiation
- Biological · Procedure · Radiation
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 1 Year · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Lymphoma
- Interventions
- aldesleukin, rituximab, therapeutic autologous lymphocytes, fludarabine phosphate
- Biological · Drug
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 16 Years to 70 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Leptomeningeal Melanoma
- Interventions
- CD8+T cells
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Hodgkin's Disease
- Interventions
- Gemcitabine, Fludarabine, Melphalan, Antithymocyte Globulin, Allogeneic Stem Cell Infusion, Tacrolimus, Filgrastim (G-CSF), Methotrexate
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- Up to 65 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2016
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Refractory Non-Hodgkin Lymphoma, Burkitt Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Diffuse Large B Cell Lymphoma, Small Lymphocytic Lymphoma, Transformed Lymphoma, Non-Hodgkin Lymphoma
- Interventions
- Fludarabine, Cyclophosphamide, anti-CD19 CAR-T cells
- Drug · Biological
- Lead sponsor
- C. Babis Andreadis
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- SARS-CoV 2
- Interventions
- SARS-CoV-2 convalescent plasma, Plasma from a volunteer donor
- Biological
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,225 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Chinle, Arizona • Phoenix, Arizona + 24 more
- Conditions
- Melanoma (Skin)
- Interventions
- aldesleukin, therapeutic tumor infiltrating lymphocytes
- Biological
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2005
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Nasopharyngeal Carcinoma
- Interventions
- Epstein-Barr virus-specific adoptive T-cells immunotherapy
- Biological
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2016
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- B-ALL, DLBCL, B ALL, Dlbcl-Ci, DLBCL Unclassifiable, DLBCL, Nos Genetic Subtypes, DLBCL Activated B-Cell Type, DLBCL Germinal Center B-Cell Type, Diffuse Large B-cell Lymphoma, HGBL, HGBL, Nos
- Interventions
- 131-I Apamistamab, CAR T-cell
- Drug · Biological
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
- Conditions
- Solid Tumor, Cancer, Recurrent Solid Tumors, Refractory Solid Tumors
- Interventions
- IMA201 Product, IMADetect®
- Biological · Diagnostic Test
- Lead sponsor
- Immatics US, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 2
- States / cities
- Pittsburgh, Pennsylvania • Houston, Texas
- Conditions
- Metastatic Melanoma, Skin Cancer
- Interventions
- Aldesleukin, Cyclophosphamide, Fludarabine, Young TIL, Total Body Irradiation (TBI)
- Drug · Biological · Radiation
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 66 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2024
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Covid-19, Sars-CoV2
- Interventions
- Multiple Doses of Anti-SARS-CoV-2 convalescent plasma
- Biological
- Lead sponsor
- Noah Merin
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 2
- States / cities
- Los Angeles, California • Baltimore, Maryland
- Conditions
- CD19+ Acute Leukemia
- Interventions
- Patient Derived CD19 specific CAR T cells also expressing an EGFRt
- Biological
- Lead sponsor
- Seattle Children's Hospital
- Other
- Eligibility
- 1 Year to 26 Years
- Enrollment
- 167 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2036
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Oakland, California • Seattle, Washington
- Conditions
- Ovarian Cancer, Peritoneal Cavity Cancer
- Interventions
- therapeutic autologous lymphocytes
- Biological
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years to 75 Years · Female only
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2010
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Recurrent Acute Lymphoblastic Leukemia, Recurrent Mantle Cell Lymphoma, Refractory Chronic Lymphocytic Leukemia, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Lung Non-Small Cell Cancer AJCC v7, Unresectable Lung Non-Small Cell Carcinoma
- Interventions
- Laboratory Biomarker Analysis, ROR1 CAR-specific Autologous T-Lymphocytes
- Other · Biological
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- B-All, Acute Lymphoblastic Leukemia
- Interventions
- TSLPR-CART, Cyclophosphamide, Fludarabine
- Biological · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland